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Abstract:

Diabetes mellitus (DM) is one of the major risk factors for COVID-19 complications as
it is one of the chronic immune-compromising conditions especially if patients have
uncontrolled diabetes, poor HbA1c &/or irregular blood glucose levels. Diabetic patient’s
mortality rates with COVID-19 are higher than cardiovascular or cancer patients. Recently
Bacillus Calmette–Guérin (BCG) has shown successful results in reversing diabetes in both
rats and clinical trials based on different mechanisms from aerobic glycolysis to Beta cells
regeneration. BCG is a multi-face vaccine that has been used extensively in protection from
TB and leprosy and has been repositioned for treatment of bladder cancer, diabetes &
multiple sclerosis. Recently, the COVID-19 epidemiological study confirmed that
universal BCG vaccination reduced morbidity and mortality in certain geographical areas.
Countries without universal policies of BCG vaccination (Italy, Nederland, USA) have
been more severely affected compared to countries with universal and long-standing BCG
policies that have shown low numbers of reported COVID-19 cases. Some countries have
started clinical trials that included a single dose BCG vaccine as prophylaxis from COVID19 or an attempt to minimize its side effects. This proposed research aims to use BCG
vaccine as a double-edged weapon countering both COVID-19 & diabetes, not only as
protection but also as therapeutic vaccination. The work includes a case study of
regenerated pancreatic beta cells based on improved C-peptide & PCPRI laboratory
findings after BCG vaccination for a 9 years’ patient. The patient was re-vaccinated based
on a negative tuberculin test & no scar at the site of injection of the 1st BCG vaccination at
birth. Furthermore, the authors in the present article described a prospective BCG multidose clinical study in full details that they will apply in case of acceptance of their submitted
grant & the ethical committee approval. The aim of the clinical study is to check if double
dose BCG (4 weeks apart) will show a significant difference in the protection of health care
professionals in Egypt. The authors suggest and invite the scientific community to take into
consideration the concept of direct BCG re-vaccination (after 4 weeks) because of the
reported gene expressions & exaggerated innate immunity consequently. As the diabetic
MODY-5 patient (mutation of HNF1B, Val2Leu) was on low dose Riomet® while
eliminating insulin gradually, a simple analytical method for metformin assay was
recommended to ensure its concentration before use as it is not approved yet by the
Egyptian QC labs.
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COVID-19; Multi-dose BCG; Beta cells regeneration; Improved C-peptide; Serendipity.
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1. Introduction:
Diabetic patients are more liable to develop serious complications from COVID-19
in a mechanism like its sister virus (MERS-CoV) that binds to the receptor-binding domain
of dipeptidyl peptidase IV promoting pulmonary inflammation and macrophage infiltration
[1]. Many recent COVID-19 studies reported that diabetes was a major contributing factor
either for non-survivals &/or hospitalization, representing 12% of non-survivors [2] and
22% of the hospitalized patients in another study [3]. Generally, people with Diabetes
Mellitus are most likely to suffer from different complications when infected with the virus
ranging from mild to severe. Diabetic patients with uncontrolled blood glucose are more
liable to respiratory tract infection due to their compromised immunity [3-4].
Recent literature has linked and introduced the term “trained immunity” to BCG
vaccine. BCG vaccine achieves this effect by inducing pattern recognition receptor NOD2,
resulting in metabolic changes with epigenetic rewiring [5]. The reasoning behind the
initiating of this process is immunomodulation [6]. This immune-modulatory mechanism
of BCG was reported to limit the progression of autoimmune Type 1 Diabetes Mellitus
(T1D) and Multiple sclerosis (MS). Tumor necrosis factor (TNF) is a cytokine with proinflammatory properties and immune-stimulatory features that is deficient in both TID and
MS autoimmune diseases. In T1D, there is an imbalance between overexpression of
pathogenic cytotoxic T cells (CD8 CTLs) and a shortage in T-regulatory (CD4 Treg) cells.
This pathogenic imbalance could be restored with TNF which leads to proper stimulation
of T cell antigen presenting cells and mediates elimination of auto-reactive T cells causing
T1D and MS. BCG vaccination is considered a potent TNF inducer that replenishes TNF
deficiency [9].
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BCG vaccine possesses a deep-rooted safety profile. Adverse effects are mainly due
to inefficient application as deep injection or incorrect dose. Although BCG is known
frequently to cause local reactions, anaphylaxis is a rare side effect. It has existed for 80
years now and is one of the most commonly used of all current vaccines with 80%
worldwide coverage [10]
We propose using BCG as double-edge weapon for both COVID-19 & diabetes,
not only for protection but also as therapeutic vaccination. The work included is a case
study of regenerated pancreatic beta cells based on C-peptide & PCPRI laboratory findings
after BCG vaccination for a 9 year old patient. Furthermore, the authors in the present study
described a prospective BCG multi-dose clinical study in full details that they will apply in
case of acceptance of their submitted grant & the ethical committee approval (code
CL/2005). The aim of the clinical study is to validate if double dose BCG (4 weeks apart)
will provide a significant difference in protection of the Egyptian health care professionals
against COVID-19. The authors suggest and invite the scientific community to take into
consideration the concept of direct re-vaccination (after 4 weeks) because of the reported
changes in genes expressions & exaggerated stimulation of innate immunity.
We assume that BCG had a role in the regeneration of beta cells of pancreas in the
underlying case study based on the increase of the postprandial C-peptide value from 1.53
ng/mL (before BCG vaccination) to 4.88 ng/mL after 5 weeks of post BCG vaccination.
Recently, the molecular mechanism involving the immune-stimulatory activity of foreign
nucleic acids through cytosolic DNA sensing has been progressing. Both cyclic GMP-AMP
synthase (cGAS) and stimulator of interferon genes (STING) pathway are stimulated upon
recognition of cytosolic DNA leading to type I interferons stimulation [11]. Type I IFNs is
then achieve a reported role in enhancing and promoting pathways of innate immunity, plus
its support in developing adaptive immunity via increasing pro-inflammatory cytokines like
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IL-12P70 [12]. It was recently reported that up-regulation of some genes contribute in BCG
activity as IL17F gene with its associated cytokines IL22, IL23A, and FCGR1B [13]. Other
studies proposed that up-regulation of ICAMI gene (Intercellular Adhesion Molecule-1
gene) is responsible of a part of BCG activity. ICAM-1 is a trans-membrane protein
important for several basic immunological processes, including antigen presentation to T
lymphocytes and leucocytes extravasation. This is especially crucial in case of using BCG
as antitumor agent [14].
Finally, as the diabetic case study was on low dose Riomet ® while eliminating
insulin gradually, a simple analytical method for metformin assay was recommended to
ensure its concentration before use as it is not approved yet by the Egyptian QC labs. Some
parameters were adjusted according to previous LC work [15] on metformin combinations
while the previous LC-MS work on metformin [16] was excluded to avoid its high cost.
ICH guidelines [17] were applied for the method validation.
2. Results & discussion
2.1. COVID-19, Diabetes & BCG
Diabetic patients are at higher risk of COVID-19 infection especially poor
controlled patients. Diabetes increases mortality in patients infected with H1N1, SARS,
and MERS-CoV. Also, diabetes is responsible for 42.3% of 26 COVID-19 fatalities in
Wuhan, China [4, 18, and 19]. Recent reports in correspondence to different clinical data
shows that fatalities in hypertensive and diabetic patients are higher with COVID-19
infection. COVID-19 virus binds to its target via angiotensin-converting enzyme 2 (ACE2)
on epithelial cells of the lungs, kidney, blood vessels and intestine. On the other hand, the
expression of ACE2 is elevated in type 1 and type 2 diabetic cardiovascular patients who
have been long treated with ACE inhibitors and angiotensin II receptor blockers (ARBs)
leading to up-regulation of ACE2. Additionally, ACE2 up-regulation may occur via using
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thiazolidinediones in type 2 diabetes mellitus. As a result, patients with diabetes and
hypertension have higher risk of developing severe presentation and fatal outcome from
COVID-19 [20-21]
BCG reported to initiate a memory-like innate immune training rather than its
known adaptive immune rule as a vaccine. This recently discovered mechanism is through
transcriptional modification on bone marrow hematopoietic stem cells in multipotent
progenitors (MPPs). This in turn promotes an expansion and differentiation in
hematopoietic stem cells with unintended, yet desirable behavior. Collectively, BCG
vaccine would motivate production of bone marrow derived macrophages/monocytes
which are minded epigenetically to proceed more protective actions against tuberculosis
[22].
In addition to this role in training immunity, BCG is used as a therapy for bladder
carcinoma. Clinical studies show its ability to reduce cancer recurrence and further
progression, in comparison with other anticancer agents. Being antitumor agent is mainly
due to its capacity to promote TNF levels [23]. These studies show the essential need for
more understanding of the behavior of those immune trainers chiefly BCG molecularly and
clinically which would reveal more data for widening the therapeutic approaches for critical
diseases within human defected immunity including possible repurposing as therapeutic
vaccination against COVID-19 at least to develop less severe symptoms.
Regarding BCG vaccine safety, there is a small margin of risk, however as BCG
vaccine is a live attenuated vaccine, which might lead to infection within 8 to 12 weeks and
this must be taken into consideration with immunosuppressed individuals or with infection
of HIV. Moreover, BCG over reprograming of the immunity causes more activated CD4 T
cells which is convenient target for HIV replication. Less likely BCG contributes to
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dysfunction of cell mediated immunity; phagocytes and IFN-γ mediated pathways. In
clinical trials using BCG in treatment of cancer bladder, only 5% of patients were presented
with complication as reactive arthritis in large joints due to multiple intravesical
administration of the vaccine [24].
However, BCG randomized controlled clinical trials were proved to be the most
widely acceptable due to its safety ratios in comparison to other therapeutic agents. This
relative supremacy makes it the only infancy vaccine which can be used in clinical trials
with long periods of investigation, generally BCG possess a stable abiding positive effect
on health [25].
BCG multi-dose clinical trials in Egypt may show different results than those
obtained from US volunteers’ multi-dose long term study that was targeting diabetes [26]
due to ethnic and genetic factors [27-29]. Ethnic difference has been taken in consideration
in recent years. Typically, global companies start clinical development in Japan after the
United States and Europe, some genetic factors could explain a significant proportion of
dose variability of many drugs between different ethnic groups [28-29]. The recognition of
racial differences in disease outcome may explain a significant proportion of dose
variability. This evidence underpins the prevailing hypothesis that genotype guided therapy
should improve dosing accuracy [28-29].
2.2. Case study of beta cells regeneration after BCG by serendipity
Case presentation
A nine years old male patient was admitted to the emergency department with
random blood glucose of 580 mg/dL and a history of polyuria, polydipsia without
ketoacidosis. Diabetes Mellitus type-1 was suspected and accordingly insulin therapy
began. The patient was treated successfully and discharged from the hospital one day later
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on insulin regimen. On discharge, the patient performed the following lab studies; fasting
blood glucose and postprandial blood glucose (FBS/PPBS), glycosylated hemoglobin
(HbA1c), postprandial C-peptide, complete urine analysis. In addition, Insulin/islet
cell/IA2/glutamic acid decarboxylase antibodies, hematological, thyroid, liver, renal
functions, electrolytes, CRP, CBC, Anti tissue IgA, IgG, G6PD, TIBC, iron, serum ferritin,
vitamin D, food intolerance test, lipid proﬁle and ApoB/ApoA were also recommended due
to his parents medical background. At that time, the patient’s average blood glucose was
80 to150 mg/dL FBS and 170 to 250 mg/dL PPBS with insulin therapy and multiple
correction doses. Ultrasound on the abdomen showed normal size and images for the
pancreas, liver, kidneys, spleen, appendix, gall bladder, intestines, urinary bladder & blood
vessels of the abdomen. No aneurysm or any other abnormal finding was found in the
ultrasound investigation. All laboratory results before BCG intradermal administration are
shown in (table 1).
His C-peptide was 1.53 ng/mL, PPBS was 273 mg/dL, HbA1c was 9.6 % and only
glutamate decarboxylase antibody was positive (33.5 U/mL). His complete blood picture,
thyroid, liver function, kidney function and lipid proﬁle & all the other laboratory
investigations were all in the normal range (table 1). Postprandial C-peptide/blood glucose
ratio (PCPRI) was calculated and found to be 0.56. Clinical exome sequencing on Illumina
Hiseq2500 platform (Illumina Inc., USA) was performed at Generation Lab (Cairo, Egypt).
Rare and non-silent variants in 12 maturity-onset diabetes of the young (MODY) genes
were investigated for pathogenicity. A rare missense variant (HNF1B, Val2Leu) in MODY
genes was identiﬁed.
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Table 1: Laboratory investigation findings before BCG intradermal administration
Laboratory investigation
Glycated Hemoglobin (HbA1c)

Result
9.6 %

C-Peptide (postprandial)
Plasma glucose 2hrs PP
Glutamate Decarboxylase Antibodies

1.53 ng/mL
273 md/dL
33.5 U/mL

IA2 Antibodies

0.16 U/mL

Insulin Antibodies

3.6 %

Anti-Islet cell Antibodies
Anti-tissue transglutaminase IgA

Negative
1.1 U/mL

Anti-tissue transglutaminase IgG

0.9 U/mL

C-reactive protein (CRP)
Homocysteine
Serum cholesterol

0.1 mg/L
14.7 umol/L
181 mg/dL

HDL-Cholesterol

74 mg/dL

LDL

96 mg/dL

Non-HDL-Cholesterol
Serum Triglycerides

107 mg/dL
57 md/dL

Serum VLDL Cholesterol
T. cholesterol / HDL Cholesterol
LDL/HDL Cholesterol
Serum Apo A1
Serum Apo B

11 mg/dL
2.45
1.3
190 mg/dL
69 mg/dL

Serum ApoA1/Apo B
25(OH) Vitamin D

2.75
21.28 ng/mL

Serum urea

41 mg/dL

Reference range
4.5 – 5.7, Normal range
5.8 – 6.4, Prediabetic
> 6.5, Diabetic
6 – 7, Good control
7 - 8, Fair control
>8, Poor control
2.7 – 5.6
70 - 140
Negative if < 10
Positive if > or = 10
Negative if < 1 U/mL
Grey zone if 1 - 2 U/mL
Positive if > 2 U/mL
Negative if < 8.2
Positive if > or = 8.2
Negative
Negative if < 10
Positive if > or = 10
Negative if < 10
Positive if > or = 10
<5
3.7 – 13.9
Up to 170 Desirable
Over 200 High risk
Up to 40 High risk
Over 60 Low risk
Up to 110 Acceptable
110 - 129 Borderline
Over 130 High
Up to 130 Optimal
Up to 150 Normal
150 - 199 Borderline
200 - 499 High
Up to 30
Less than 4.44
Less than 3.22
>120 recommended
0 – 100 Desirable
Over 120 High risk
More than 1
<20 Deficiency
21-29 Insufficiency
30-100 Sufficiency
Over 150 Hypervitaminosis
10.8-38.4
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Serum Creatinine
0.74 mg/dL
0.39-0.8
Serum uric acid
2.6 mg/dL
3.5-7.2 mg/dL
ALT (SGPT)
11 U/L
0-50
AST (SGOT)
22 U/L
0-50
Bilirubin (total)
0.34 mg/dL
0.3-1.2
Bilirubin (direct)
0.07 mg/dL
Up to 0.2
A/G ratio
1.47
1-2
Albumin, serum
4.7 g/dL
3.8-5.4
Total protein, serum
7.9 g/dL
5.7-8
TSH
2.893 uIU/mL
0.3-4.5
Free T3
3.61 pg/mL
2.3-5.3
Free T4
1.45 ng/dL
0.77-1.32
PTH
30.4 pg/mL
6-80
Serum calcium (total)
10.2 mg/dL
8.8-10.8
Ionized calcium (Ca++)
4.8 mg/dL
4.8-5.5
Serum phosphorus
5 mg/dL
3.2-5.8
Iron, serum
51 ug/dL
50-120
Total iron binding capacity (TIBC)
362 ug/dL
250-400
+
Serum potassium (K )
4 mmol/L
3.5-5.1
Serum sodium (Na+)
139 mmol/L
136-146
Serum magnesium
2.1 mg/dL
1.8-2.6
G6PD Activity (quantitative)
364 U/1012 RBCs 221-570
Random albumin-urea
2 mg/dL
Up to 14 mg/dL
N.B. IgE specific for 30 different food allergens did not show any significant reaction (all <0.35
IU/mL). Urine analysis showed no significant findings. CBC showed no pathogenic markers.
No ketone bodies, bilirubin, uro-bilirubin &/or albumin were found in urine and its microscopic
examination showed normal results. Complete FoodPrint ® IgG antibody test for 200 food groups
showed positive results (>30 U/mL) for Casein (& all dairy), Gluten (& all wheat) and some
nuts.

BCG Vaccination outcomes
Although BCG vaccination has been compulsory in Egypt since 1974 and the
patient was vaccinated directly after birth; the patient has no vaccination scar and tested
tuberculin negative [30]. And as the patient has family history of TB, BCG re-vaccination
in a Ministry of Health office with the standard dose of 0.05 ml in the lateral upper part of
the left shoulder was done [31]. After 2-3 weeks of BCG vaccination, the patient showed
many hypoglycemic episodes that was attributed to gradually increase his own insulin
secretion. Insulin was tapered and metformin (Riomet®) was introduced. Four weeks after
vaccination, metformin was stopped. Five weeks post vaccination, his daily routine
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monitoring of blood glucose for FBS/PPBS was 89 and 153 mg/dl with no insulin therapy
and no oral hypoglycemic drugs. Also, the above-mentioned lab studies (before
vaccination) were repeated and all results after BCG intradermal administration are shown
in (table 2), C-peptide was 4.88 ng/mL and HbA1c was 7%. His postprandial Cpeptide/blood glucose ratio (PCPRI) was calculated and found to be 3.2 )311 * 351/8.44(
In 1997 Horikawa et. al. reported the first case of Maturity onset diabetes of the
young subtype 5 (MODY5) [32]. We herein report a mutation in the HNF1B gene of a 9years-old Egyptian patient with atypical non autoimmune diabetes phenotype of MODY5
reflecting extensive clinical and genetic heterogeneity of the disease. In patients with
mutation of HNF1B gene, the primary pathophysiology of diabetes in (Mody5) is
characterized by decreased insulin secretion with progressive hyperglycemia due to
pancreatic atrophy [33-35]. Accordingly, when our patient was diagnosed with diabetes,
insulin treatment was required due to defective insulin secretion associated with pancreatic
atrophy [36]. However, upon BCG re-vaccination, after 5 weeks, the patient was near
normo-glycemic range with no insulin therapy, so we presumed there was restored insulin
secretion due to pancreatic beta cells regeneration.
C-peptide value was increased to 4.88 ng/mL (from 1.53 ng/mL) after vaccination
(more than 3 times). Moreover, PCPRIA was increased to 3.2 from 0.56 (more than 5
times). It has been proven that the mechanism of near normal blood sugar restoration
following BCG treatment is due to the regeneration of insulin-secreting islets of pancreas
[26, 37 and 38]. As previously published, the stimulation in tumor necrosis factor (TNF)
after BCG vaccine increases both cytotoxic T cell death and Treg expansion [39-41] .
C-peptide is co-secreted with insulin from the pancreas and can be used to selectively detect
the secretion of endogenous insulin [42-43]. A comparison between the patient’s C- peptide
pre-vaccination and post-vaccination of 1.53 ng/ml and 4.88 ng/ml respectively is proof of
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a similar mechanism of pancreatic islet regeneration. Accordingly, we observed the stable
lowering of blood sugars after BCG vaccinations; FBS/PPBS is 89 and 153 mg/dl with no
insulin therapy compared to FBS/PPBS 80 to150 mg/dl and 170 to 250 mg/dl before BCG
vaccination with insulin therapy (0.5 unit/kg/day).
Table 2: Laboratory investigation findings after BCG intradermal administration
Laboratory investigation
Glycated Hemoglobin (HbA1c)

Result
7%

C-Peptide (postprandial)
Plasma glucose 2hrs PP
Fasting plasma glucose (without insulin)
(& without oral hypoglycemic drugs)
Blood viscosity
ESR
Serum Amylase
Lipase level in serum
Serum ferritin
Rheumatoid factor
C-reactive protein (CRP)
Homocysteine
Serum cholesterol

4.88 ng/mL
153 md/dL
89 mg/dL

HDL-Cholesterol

72 mg/dL

LDL

104 mg/dL

Non-HDL-Cholesterol
Serum Triglycerides

115 mg/dL
56 md/dL

Serum VLDL Cholesterol
T. cholesterol / HDL Cholesterol
LDL/HDL Cholesterol
Serum Apo A1
Serum Apo B

11 mg/dL
2.6
1.44
192 mg/dL
70 mg/dL

Serum ApoA1/Apo B
ACTH (am)

2.74
28.2 pg/mL

1.8
6 mm
80 U/L
27 U/L
59.9 ng/mL
8.78 IU/mL
0.3 mg/L
10.68 umol/L
187 mg/dL

Reference range
4.5 – 5.7, Normal range
5.8 – 6.4, Prediabetic
> 6.5, Diabetic
6 – 7, Good control
7 - 8, Fair control
>8, Poor control
2.7 – 5.6
70 - 140
70-100
1.4-1.8
3-12 mm
28-100
Up to 60
21.81-274.66
Up to 14
<5
3.7 – 13.9
Up to 170 Desirable
Over 200 High risk
Up to 40 High risk
Over 60 Low risk
Up to 110 Acceptable
110 - 129 Borderline
Over 130 High
Up to 130 Optimal
Up to 150 Normal
150 - 199 Borderline
200 - 499 High
Up to 30
Less than 4.44
Less than 3.22
>120 recommended
0 – 100 Desirable
Over 120 High risk
More than 1
Less than 65
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Serum urea
40 mg/dL
10.8-38.4
Serum Creatinine
0.64 mg/dL
0.39-0.8
Serum uric acid
4.1 mg/dL
3.5-7.2 mg/dL
ALT (SGPT)
16 U/L
0-50
AST (SGOT)
31 U/L
0-50
Bilirubin (total)
0.34 mg/dL
0.3-1.2
Bilirubin (direct)
0.07 mg/dL
Up to 0.2
Alkaline phosphatase
201 U/L
42-362
TSH
3.61 uIU/mL
0.3-4.5
Free T3
3.57 pg/mL
2.3-5.3
Free T4
1.22 ng/dL
0.77-1.32
GH
5.11 ng/mL
Up to 3
Cortisol (9 am)
18.14 µg/dL
4.3-22.4
Serum calcium (total)
10.2 mg/dL
8.8-10.8
Ionized calcium (Ca++)
4.9 mg/dL
4.8-5.5
Serum phosphorus
4.7 mg/dL
3.2-5.8
Iron, serum
94 ug/dL
50-120
Serum potassium (K+)
3.8 mmol/L
3.5-5.1
+
Serum sodium (Na )
134 mmol/L
136-146
N.B. Urine analysis showed no significant findings. No ketone bodies, bilirubin, uro-bilirubin
&/or albumin were found in urine and its microscopic examination showed normal results.

Therefore, we concluded that the BCG re-vaccinations did induce a clinically
meaningful return of C-peptide levels in the pancreas by regeneration, as reflected on the
patient’s blood glucose level & postprandial C-peptide levels.
It is worthy to mention that some other lab investigations were requested by the
parents to exclude secondary diabetes &/or pancreatitis and to check the overall health of
the patient and all of them showed good results in the normal range including ESR, blood
viscosity, ACTH, Cortisol, GH, Rheumatoid factor, Amylase and Lipase. All the results for
the previously mentioned laboratory investigations are shown in (table 2).
BCG re-vaccination after four weeks was used by kuhtreiber et al. in his work
published at NPJ vaccines [26] with one of the most interesting outcomes of multi-dose
BCG human clinical trials suggesting aerobic glycolysis as the mechanism of action for
BCG anti-hyperglycemic effect. BCG re-vaccination (after 4 weeks) resulted in
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demethylation of regulatory T cell signature genes in vivo with enhanced mRNA
expression [26]. BCG effects on the gene level are interesting especially regarding the
part related to “innate or trained” immunity. The authors not only recommend multidose BCG clinical trials for COVID-19 in Egypt, but also they invite the scientific
community and the already ongoing studies with single dose BCG to go through another
dose after 4 weeks form the start of the study. So, the frequency of BCG vaccination is
critical.
Double dose BCG did not show complications and it is well tolerated with high
safety profile & it had been proved to initiate a cycle of gene modifications that may be
the key against the current fight with COVID-19 outbreak. Single dose BCG may not
be enough for the fight against the aggressive COVID-19 and many doses (more than
2) may result in complications as the case with multiple dose intravesical BCG for
bladder cancer (although different route of administration). So the authors suggest at
least 2 doses (4 weeks apart) as that showed already high safety profile in previous
human study targeting diabetes and to ensure BCG ability to re-modulate immunity
towards our desired protective &/or treatment activity in case of cytokine storm
syndrome of the most recent COVID-19. Furthermore, the complications resulted from
frequent multi-dosing of BCG as antitumor agent mainly in bladder carcinoma are
different as direct agent responsible of tumor cells apoptosis in that protocol. Finally,
many countries like Brazil for example are still recommend BCG re-vaccination to
protect people from TB. So, what if re-vaccination also reverse diabetes & protect from
COIVD-19 as double-edge weapon especially for the first line health care workers.
Assay of metformin in Riomet® oral solution
As the diabetic case study was on low dose Riomet® while eliminating insulin
gradually, a simple analytical method for metformin assay was recommended to ensure its
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concentration before use as it is not approved yet by the Egyptian QC labs. Thermo Fisher
UPLC (Ultimate 3000, USA), Symmetry® C18 column (100 mm × 2.1 mm, 2.2 μm) &
Diode Array detector (3000RS, USA) were used with mobile phase (methanol: water,
50:50, v/v) in the isocratic mode at 237 nm. The flow rate was 0.1 mL min-1 and the injection
volume were 10 µL. Calibration curve was obtained by plotting Area under the peak against
the corresponding concentrations (2 - 50 µg/mL). Good UPLC peak was obtained (figure
1). The regression equation was found to be (AUP = 1.6664 Conc. + 1.5789, r2 = 0.9999)
where AUP is the area under the peak and r2 is the regression coefficient. LOD (limit of
detection) and (limit of quantification) were found to be (0.63 µg/mL) and (1.91 µg/mL),
respectively. STEYX (residual standard deviation of the regression line) was found to be
0.319. Sb (standard deviation of the slope) & Sa (standard deviation of the intercept) were
found to be 0.00785 & 0.29104, respectively. Confidence intervals for slope & intercept
were found to be (1.6664 ± 0.0131) & (1.5789 ± 0.459), respectively.
The developed UPLC-UV for metformin assay was validated successfully
according to ICH guidelines [17]. Metformin concentrations (5, 25, and 45 μg/mL) were
assayed three times within the same day to assess the intra-day precision while inter-day
precision was assessed on three successive days. Metformin concentrations were calculated
using the corresponding regression equation to check the accuracy of the method with n =
3 using recovery percent (R %) and it was found to be 99.56 ± 1.89 (mean ± standard
deviation). To check the precision, both intra-day and inter-day percent relative standard
deviation (% RSD) were calculated and showed values below 2%
Regarding Riomet® application, the resultant mean of recovery percent ± standard
deviation of three determinations was equal to 96.24 ± 1.33. Riomet® inactive ingredients
did not show interference confirming the specificity of the method including hydrochloric
acid, propylene glycol, glycerin, potassium bicarbonate, sucralose, xylitol. Regarding the
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system suitability tests, the number of theoretical plates was found to be 1406 while the
tailing factor of the peak was found to be 1.01. In conclusion, the simple proposed UPLC
method was proved to be suitable for determination of metformin in bulk and in Riomet®
in a reasonable run time and the obtained Riomet® recovery was optimum and suitable for
use by the patient in the case study.

Figure (1): UPLC-UV Chromatogram of metformin hydrochloride (30 µg/mL)
2.3. Prospective clinical trial (multi-dose BCG for COVID-19)
Subjects and study design
A randomized clinical trial will be conducted to test the use of multi-dose BCG
vaccine (intradermal, 4 weeks apart) as a prophylaxis from Covid-19 for 150 Egyptian
healthcare professionals (75 as control). No placebo will be used, since it is unlikely to
mimic the pustule developed following a BCG vaccination, hence the health care
volunteers were not be blinded to the intervention. However, test and control volunteers
examined by a plaster and blood samples were known by anonymized study id numbers.
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Criteria of Selection
Regarding the inclusion criteria, healthy volunteers from the health care
professionals will be included (between 20 & 50 years old). Female participants should
not be pregnant and should avoid pregnancy throughout the 3-month study. All
participants will sign an informed consent. All health care volunteers will be presented
with the material related to this study and a copy of consent for consideration as well
as contact information of research staff available to answer any questions or concerns.
Regarding the exclusion criteria, participants are not eligible for the study if they
have an acute illness or body temperature ≥37.5 degree Celsius. Participants who have
a history or evidence of any autoimmune disease, active tuberculosis, allergic disease,
immunosuppressive medication, immunoglobulin, blood products, or any chronic
illness will be excluded. Pregnant females will be excluded from the study. Participants
that test COVID-19 positive before the first BCG vaccination will be excluded from the
study.
Study Groups
75 subjects will receive intradermal BCG vaccine (2 doses, 4 weeks apart) as 0.05 ml
(20×106 colony forming units/ml) from a single dose plastic syringe through a short
beveled 10 mm 25-gauge intradermal needle, into the lower deltoid region of the right
arm at the insertion point of the muscle (as group A) while the other 75 subjects will be
considered as control (as group B). Protocol was submitted for approval by the Ethical
Committee Board at The British University in Egypt (code CL/2005). The studies will
be conducted in accordance with the Declaration of Helsinki and applicable local
regulations for conducting clinical trials on medicinal products in humans.
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Outcomes Measures
Primary Endpoint:
BCG will be assessed for its ability to mitigate the prevalence and severity of Covid19 symptoms. Blood samples, nasopharyngeal and oropharyngeal swab and sputum
samples will be collected from all participants (both test & control) before the first BCG
vaccination and at 1, 2 and 3 months after vaccination. At 1 month, all the test group
will be re-vaccinated by BCG. About 10 mL of whole blood will be drawn from each
participant and kept in a heparin treated tube to prevent coagulation, and transported to
Ain shams Specialized Hospitals and El Demerdash Hospital Central Labs for testing
SARS-CoV-2 by real-time reverse transcriptase (RT)-PCR, IgG antibodies, IgM
antibodies, highly sensitive CRP, Liver enzymes (SGPT, SGOT), D-Dimer, Serum
ferritin, ESR, CBC differentiated that should include the following, Leukocyte count,
Lymphocyte count, Neutrophil-lymphocyte-ratio (NLR) and lymphocyte subsets
(Helper T cells CD3+CD4+ & Suppressor T cells CD3+CD8+) in addition to CT scan.
Participants that test COVID-19 positive before the first BCG vaccination will be
excluded from the study.
Both Group A (test) & Group B (control) will be monitored for degree of clinical
manifestations in correlation to lab findings. RNA will be extracted from clinical
samples with a QIAamp viral RNA mini kit (QIAGEN, Hilden, Germany). All
specimens will be handled under a biosafety cabinet according to laboratory biosafety
guidelines of Ain shams University Central Labs for Control and Prevention for
COVID-19. According to the protocol issued by the National Institute for Viral Disease
Control and Prevention in China [44], two sets of primers will be used for two target
genes open reading frame 1ab [ORF1ab] and nucleocapsid protein [N]. RT-PCR assay
will be performed using a 2019-nCoV nucleic acid detection kit. A cycle threshold
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value (Ct-value) less than 37 was defined as a positive test result, and a Ct-value of 40
or more was defined as a negative test. A medium load, defined as a Ct-value of 37 to
less than 40, required confirmation by retesting [45].
Secondary Endpoint:
The secondary outcomes are the adverse events, including local and systemic ones
related to vaccination, admissions to hospital and mortality. Safety of the BCG vaccine
treatment regimens were based on the induction of adverse events that was graded
according to FDA toxicity tables for Healthy Adult and Adolescent Volunteers Enrolled
in Preventive Vaccine Clinical Trials [45]. We will record adverse events during the
first 30 days after each vaccination i.e. study days 0–30, 31–60, and during the 3-month
study period (61-90).
Novelty of the suggested multi-dose BCG clinical trial for COVID-19
As reported by the first author in a preprint submitted as a letter to the editor, BCG
Vaccine repositioning to COVID-19 is a cost-effective alternative to the traditional
vaccine approach as BCG induces non-specific protection as innate immune cells,
including monocytes and natural killer cells. It protects from TB and Leprosy while it
is suggested to treat bladder cancer and diabetes by turning on immunity and it resets
the epigenetic programming of some genes and immunity related markers [46]. The
author recommends that COVID-19 vaccination clinical trials should consider multiple
doses of BCG as some preliminary studies suggested BCG to fight COVID-19 but they
did not consider the use of multiple intradermal BCG vaccination (at least 2 doses, 4
weeks apart) for the prophylaxis (&/or treatment) of COVID-19 [46]. Recently,
COVID-19 epidemiological study confirmed that universal BCG vaccination reduced
morbidity and mortality in certain geographical areas [47]. Countries without universal
policies of BCG vaccination (Italy, Nederland, USA) have been more severely affected
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compared to countries with universal and long-standing BCG policies that showed
reduced number of reported COVID-19 cases [47]. The combination of reduced
morbidity and mortality makes BCG vaccination a potential new tool in the fight against
COVID-19. Some countries started a clinical trial that included single dose BCG
vaccine as a prophylaxis from COVID-19 or at least they predict the vaccinated health
care professional may develop less severe symptoms if got infected [46].
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